Recruiting now!

We are carrying out a clinical trial with an investigational drug that is being developed for the treatment of peripheral neuropathic pain (PNP). PNP is long lasting pain associated with nerve damage caused by other diseases, surgery or physical harm. PNP can be very difficult to treat, with existing pain killers and treatments being frequently ineffective.

The information gathered during this clinical trial may support further drug development, including larger trials in patients with neuropathic pain.

Healthy Caucasian males and females
Register your interest in this clinical trial

Study summary

This study will be conducted at our clinical trials unit in London Bridge and will involve healthy Caucasian male and female volunteers. You will need to attend a screening appointment within 21 days of admission. If successful, you will be required to be in our unit for 1 in-house stay of 5 days/4 nights. There will be 1 follow up visit 10-14 days after receiving the drug.

Study dates

Part I

Cohort 4a

  • Screening period: January 22nd-February 2nd (only 1x screening appointment required)
  • In-house period: February 5th-February 9th 2018
  • Follow-up visit: February 16th 2018

Cohort 4b

  • Screening period: January 22nd-February 2nd (only 1x screening appointment required)
  • In-house period: February 6th-February 10th 2018
  • Follow-up visit: February 17th 2018

Cohort 4c

  • Screening period: January 22nd-February 2nd (only 1x screening appointment required)
  • In-house period: February 7th-February 11th 2018
  • Follow-up visit: February 18th 2018

Who can take part?

To be eligible to take part in this study you must fit the following criteria

  • Healthy Caucasian males and females aged between 20 and 45 (inclusive)
  • You must have a Body Mass Index (BMI) within the range 18.0-25.0 kg/m² (inclusive) for healthy volunteers.
  • You must not drink more than 8 cups per day of beverage containing caffeine
  •  You must not have used tobacco in any form (e.g. smoking or chewing) or other nicotine containing products in any form (e.g. gum, patch or electronic cigarettes) for at least 3 months prior to first dosing (Healthy volunteers only, Part I-III)
  • You must not test positive for hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or alcohol abuse within the last 12 months. (Alcohol abuse is defined as a regular weekly intake of more than 14 units)
  • You must be healthy with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk (Healthy volunteers only, Part I-III)
  • You must not be on any regular medications, including over the counter medications (Healthy volunteers only, Part I-III)
  • You must not have donated blood within 16 weeks prior to first dosing
  • You must not have any history of heart-related diseases or abnormalities that show up on your ECGs
  • You must not be pregnant or breastfeeding
  • Female volunteers of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting at least one menstrual cycle before the drug administration and continuing for at least 3 months after the final study drug dose.
  • Male subjects must be willing to use appropriate contraception throughout the study and for three months after the last dose of study medication. They must also agree not to donate sperm for three months following the final administration of the study drug.

A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.

Study payment

In recognition of the time involved in taking part in this study, you will receive £870 (£290 bonus and £580 study payment) on completion of the study provided you comply fully with all the study requirements.

Get in touch
Call our team for more information: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us:

Ref: TOR_September 2017 (email_website_advert text)

The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.

Register for this clinical trial